Author

N. Logan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 5 Approach:experimental assay· 4 Organism:human· 4 Research Focus:host-pathogen & immune response· 3 Approach:genetic perturbation / CRISPR· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

B. J. Willett· 3 shared P. R. Murcia· 3 shared A. R. Teagle· 2 shared D. Wright· 2 shared G. Tyson· 2 shared M. Manali· 2 shared R. Zamoyska· 2 shared A. Kurshan· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. J. Willett

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion

A. R. Teagle, P. Castro-Sanchez, R. J. Brownlie, N. Logan, S. S. Kapoor, D. Wright, R. J. Salmond, R. Zamoyska

This study shows that deleting PTPN22 in T cells enhances initial anti-tumor effector function but accelerates T cell exhaustion, with TIM-3 expression linked to IL-2 signaling and NFIL3.

bioRxiv · Jun 24, 2023Immunology

Rising SARS-CoV-2 Seroprevalence and Patterns of Cross-Variant Antibody Neutralization in UK Domestic Cats

G. B. Tyson, S. Jones, N. Logan, M. McDonald, P. R. Murcia, B. J. Willett, W. Weir, M. J. Hosie

The paper examines SARS-CoV-2 seroprevalence and cross-variant antibody neutralization in UK domestic cats, finding a 3.2% overall seroprevalence with variant-specific responses correlating with human circulation patterns.

bioRxiv · Nov 18, 2022 · PreprintImmunology

Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5

B. J. Willett, A. Kurshan, N. Thakur, J. Newman, M. Manali, G. Tyson, N. Logan, P. R. Murcia, L. B. Snell, J. D. Edgeworth, J. Zhou, K. Sukhova, G. Amirthalingam, K. Brown, B. Charleston, , T. P. Peacock

This study compares the antigenic properties of SARS-CoV-2 Omicron variants BA.4 and BA.5 with BA.1, BA.2, and vaccine-induced antibodies, finding they are antigenically distinct and show enhanced neutralisation breadth after breakthrough infection.

bioRxiv · May 25, 2022 · PreprintMicrobiology

SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity

M. Manali, L. A. Bissett, J. Amat, N. Logan, S. Scott, E. Hughes, W. Harvey, R. Orton, E. Thomson, R. Gunson, M. Viana, B. Willett, P. R. Murcia

The paper examines how SARS-CoV-2 evolution and patient immunological history influence antibody breadth and potency against different variants.

bioRxiv · May 6, 2022Microbiology

Development of highly potent neutralising nanobodies against multiple SARS-CoV-2 variants including the variant of concern B.1.351

A. M. Sziemel, S.-H. Hwa, A. Sigal, G. Tyson, N. Logan, B. J. Willett, P. J. Durcan

This paper develops potent neutralizing nanobodies against SARS-CoV-2 variants, including B.1.351, to address reduced vaccine efficacy.

bioRxiv · Apr 11, 2021 · PreprintImmunology

CRISPR-mediated deletion of the Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) improves human T cell function for adoptive T cell therapy

S. Prade, D. Wright, N. Logan, A. R. Teagle, H. J. Stauss, R. Zamoyska

This study shows that deleting PTPN22 in human T cells enhances their cytokine production and anti-tumor activity, suggesting improved function in the tumor microenvironment.

bioRxiv · Dec 3, 2020 · PreprintImmunology